AI assistant
COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2018
Jan 30, 2018
32163_dirs_2018-01-29_1914da02-d08d-4492-96c8-2bc650765298.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2018-01-25
Reporting Person: Heffernan Michael Thomas (Director, Chairman, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-01-25 | Common Stock | A | 75000 | — | Acquired | 593987 | Direct |
| 2018-01-26 | Common Stock | A | 1044 | $10.17 | Acquired | 595031 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-01-25 | Stock Option (Right to Purchase) | $24.35 | A | 150000 | Acquired | 2028-01-25 | Common Stock (150000) | Direct |
Footnotes
F1: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock.
F2: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3: The option vests and becomes exercisable over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2019, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer.